Search results
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 4 days agoKeytruda, 74.8%, survived for 2.5 years without their cancer recurring. That compares to 55.6% for ...
To Your Good Health: The cause behind a case of CMML seems to be unknown
The Marshall News Messenger· 2 days agoAccording to his death certificate, he died of lung cancer (not a surprise) and chronic...
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
Zacks via Yahoo Finance· 4 days agoSummit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental...
J&J-backed Bright Peak secures $90m to advance immunoconjugate programme
Pharmaceutical Technology via Yahoo Finance· 4 days agoLast year, Keytruda generated $25bn in sales while Opdivo accumulated $9bn in revenue. Meanwhile,...
Medical breakthroughs discovered on International Space Station
Fox News via Yahoo News· 1 day agoConducting experiments in microgravity at the International Space Station has allowed scientists to ...
Biotech Insiders Share Five Lessons From Pioneering New Medicines
Forbes· 6 days agoWhy does this matter for patients? Enter the cutting-edge biotech and pharma companies who embark on the grueling, risky, and time-consuming path to developing a first-in-class drug ...
Why Moderna Stock Is a No-Brainer Buy Right Now
Motley Fool via Yahoo Finance· 6 days agoMore to come Primarily because...has no approved vaccines. With Merck, Moderna is testing a combination of Merck's Keytruda with Moderna's experimental ...
Is Merck & Co. Inc. (NYSE:MRK) The Best Healthcare Stock to Buy in 2024?
Insider Monkey via Yahoo Finance· 3 days agoWe recently published a list entitled Billionaire Israel Englander’s Top 10 Stock Picks for 2024....
